Bevacizumab in breast cancer: Fundamental questions remain

The Lancet Oncology

Volumn 14, Issue 2, 2013, Pages 99-101

  Miles, David W ^a  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; PACLITAXEL; VASCULOTROPIN A;

ALOPECIA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER MORTALITY; CANCER PROGNOSIS; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG CHOICE; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEALTH STATUS; HUMAN; HYPERTENSION; LETTER; NAIL DISEASE; NEUROPATHY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL TIME; UNITED STATES;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; PACLITAXEL;

EID: 84873839314     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70012-3     Document Type: Letter

References (10)

1. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666-2676.
2. Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010, 28:3239-3247.
3. Robert NJ, Dieras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative locally recurrent or metastatic breast cancer. J Clin Oncol 2011, 29:1252-1260.
4. Lang I, Brodowicz T, Ryvo L, et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. Lancet Oncol 2013, 14:125-133. on behalf of the Central European Cooperative Oncology Group.
5. Fojo T, Wilkerson J Bevacizumab and breast cancer: the E2100 outlier. Lancet Oncol 2010, 11:1117-1119.
6. Saad ED, Katz A, Buyse M Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials. J Clin Oncol 2010, 28:1958-1962.
7. Lee CK, Stockler MR, Coates AS, et al. Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer. Br J Cancer 2010, 102:1341-1347. for the Australian New Zealand Breast Cancer Trials Group.
8. Guyatt G, Schunemann H How can quality of life researchers make their work more useful to health workers and their patients?. Qual Life Res 2007, 16:1097-1105.
9. Miles DW, de Haas SL, Dirix L, et al. Plasma biomarker analyses in the AVADO phase III randomized study of first-line bevacizumab plus docetaxel in patients with human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer. Cancer Res 2010, 70(suppl 24):S235. (abstr P2-16-04).
10. Gianni L, Romieu G, Lichinitser M, et al. First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) plus docetaxel (DOC) as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC). Cancer Res 2011, 71(suppl 24):S109. (abstr S4-8).